Dr Reddys Laboratories announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the U.S. Food and
Drug Administration (USFDA).
The INVANZ brand and generic market had U.S. sales of approximately $205 million MAT for the most recent twelve months ending in March 2021 according to IQVIA Health.
Dr. Reddy's Ertapenem for Injection, 1 g/vial, is available in packs of 10 vials per carton.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
